VivoSeq
Other

Nicotinamide

0

Pipeline Programs

2

Active Trials

0

Companies Involved

Nicotinamide is an early-stage landscape with 0 programs across 0 companies.

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

78/100

Attrition Rate

17/100

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

12

clinical trials

Completed7 · 58%
Terminated2 · 17%
Recruiting2 · 17%
Unknown status1 · 8%

Trial Activity

12 trials

Topical Nicotinamide in Treatment of DLE
Completed··Phase 1·NCT05362188·60 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)